10-Q
Quarterly Report
60 DEGREES PHARMACEUTICALS, INC.
SXTPW
NASDAQ
CIK: 1946563
File #: 001-41719
Balance Sheet
46 line items · 2 periods
XBRL
| Item | Jun 30, 2025 | Dec 31, 2024 |
|---|---|---|
ASSETS: | ||
Current Assets: | ||
Cash and Cash Equivalents | 1,966,930 | 1,659,353 |
Accounts Receivable | 295,034 | 486,748 |
Prepaid and Other Assets | 782,970 | 1,068,940 |
Short-Term Investments | 0 | 1,728,472 |
Inventory (Note 3) | 799,421 | 442,764 |
Total Current Assets | 3,844,355 | 5,386,277 |
Property and Equipment, net (Note 4) | 193,879 | 149,808 |
Other Assets: | ||
Long-Term Prepaid Expense | 0 | 66,176 |
Intangible Assets, net (Note 5) | 143,704 | 157,084 |
Total Other Assets | 143,704 | 223,260 |
Total Assets | 4,181,938 | 5,759,345 |
LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||
Current Liabilities: | ||
Accounts Payable and Accrued Expenses | 905,813 | 1,007,618 |
SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
Derivative Liabilities (Note 8) | 776,172 | 640,830 |
Contingent Milestone Payment - Fair Value, Inputs, Level 3 - Fair Value, Recurring | 776,172 | 640,830 |
Fair Value, Inputs, Level 3 - Fair Value, Recurring | 776,172 | 640,830 |
Fair Value, Inputs, Level 3 | 776,172 | 640,830 |
Derivative Liabilities | 776,172 | 640,830 |
Fair Value, Inputs, Level 3 - Derivative Liabilities | 776,172 | 640,830 |
Total Current Liabilities | 1,690,757 | 1,657,220 |
Long-Term Liabilities: | ||
SBA EIDL (including accrued interest) (Note 7) | 145,477 | 147,119 |
Total Long-Term Liabilities | 145,477 | 147,119 |
Total Liabilities | 1,836,234 | 1,804,339 |
SHAREHOLDERS' EQUITY: | ||
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively (Note 6) | 9,567,439 | 9,567,439 |
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,472,891 and 566,908 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively(1) (Note 6) | 147 | 57 |
Additional Paid-in Capital(1) | 36,856,091 | 34,860,590 |
Accumulated Other Comprehensive Income | 142,809 | 135,471 |
Accumulated Deficit | (44,138,232) | (40,527,957) |
60P Shareholders’ Equity: | 2,428,254 | 4,035,600 |
Noncontrolling Interest | (82,550) | (80,594) |
Total Shareholders' Equity | 2,345,704 | 3,955,006 |
Common Stock, par value $0.0001 per share | 147 | 57 |
Series A - Preferred Stock | 9,567,439 | 9,567,439 |
Additional Paid-In Capital | 36,856,091 | 34,860,590 |
Accumulated Deficit | (44,138,232) | (40,527,957) |
Accumulated Other Comprehensive Income (Loss) | 142,809 | 135,471 |
Total Shareholders’ Equity (Deficit) Attributable to 60P | 2,428,254 | 4,035,600 |
Noncontrolling Interest on Shareholders | (82,550) | (80,594) |
Total Liabilities and Shareholders' Equity | 4,181,938 | 5,759,345 |